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Abstract
AIM: To investigate the effects of tachyplesin on the cell
cycle regulation in human hepatcarcinoma cells.
METHODS: Effects of tachyplesin on the cell cycle in human
hepatocarcinoma SMMC-7721 cells were assayed with flow
cytometry. The protein levels of p53, p16, cyclin D1 and
CDK4 were assayed by immunocytochemistry. The mRNA
levels of p21WAF1/CIP1 and c-myc genes were examined with
in situ hybridization assay.
RESULTS: After tachyplesin treatment, the cell cycle
arrested at G0/G1 phase, the protein levels of mutant p53,
cyclin D1 and CDK4 and the mRNA level of c-myc gene
were decreased, whereas the levels of p16 protein and
p21WAF1/CIP1 mRNA increased.
CONCLUSION: Tachyplesin might arrest the cell at G0/G1 phase
by upregulating the levels of p16 protein and p21WAF1/CIP1 mRNA
and downregulating the levels of mutant p53, cyclin D1 and
CDK4 proteins and c-myc mRNA, and induce the differentiation
of human hepatocacinoma cells.
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INTRODUCTION
A variety of anticancer agents with distinctive effects have
been used for treatment of malignant tumors. These agents
generally induce tumor cell necrosis and apoptosis as well as
differentiation. Today, induction of differentiation is a new
strategy in cancer therapy[1-6]. A number of recent experiments
have showed that cell-cycle-arrest may be necessary for cell
differentiation. The current knowledge of cell cycle regulation
have revealed that the progression of the cell cycle is governed
mainly by the activation and deactivation of cyclin-dependent
kinases (CDKs). In order for cell cycle arrest to differentiation,
it is necessary either to downregulate positive regulation of
CDKs, such as cyclins, or to activate negative regulators of
CDKs, such as CDK inhibitors (CKIs)[7].
      It had revealed that tachyplesin, a low molecular weight
peptide, could alter the morphological and ultrastructural
characteristics, inhibit the proliferation and induce the
differentiation of human gastric carcinoma cells and
hepatocarcinoma cells[8,9]. In this paper, we investigate the




Tachyplesin was isolated from acid extracts of Chinese
horseshoe crab (Tachypleus tridentatus) hemocytes as
described by Nakamura[10] with minor modification. RPMI-
1640 medium were obtained from Gibco. Fetal calf serum was
supplied by Si-Ji-Qing Biotechnology Co. (Hangzhou, China).
Mouse anti-human p53, p16, cyclin D1 monoclonal antibodies
and rabbit anti-human CDK4 antibody were purchased from
Santa Cruz. Immunocytochemistry detection kit and in situ
hybridization kit were provided by Beijing Zhongshan
Biotechnology Co.
Cell culture and treatment
SMMC-7721 cells, provided by the Institute of Biochemistry
and Cell Biology, Shanghai Institute of Biological Sciences,
Chinese Academy of Sciences, were maintained in RPMI-1640
medium supplemented with 20 % heat-inactivated fetal calf
serum, 100 units/mL penicillin, 100 mg/L streptomycin and
50 mg/L kanamycin at 37 , 5 % CO2 in air atmosphere.
SMMC-7721 cells were treated with culture medium containing
3.0 mg/L tachyplesin after being seeded for 24 hours.
Flow cytometry assay
SMMC-7721 cells and the cells treated with 3.0 mg/L
tachyplesin for 2, 4 or 6 days were collected, rinsed in 0.1 M
PBS, resuspended and fixed in 70 % ethanol at 4  overnight.
Cells were centrifuged, resuspended in 100 mg/L RNase A at
37  for 30 min and in 50 mg/L propidium iodide at 4  for
30 min. Cell cycle was analyzed by flow cytometry.
Immunohistochemistry analysis
SMMC-7721 cells and the cells treated with 3.0 mg/L
tachyplesin for 5 days were seeded in little penicillin bottles
with coverslips for 48 hours respectively. The cells grown on
coverslips were fixed with cold acetone for 10 min, rinsed
twice in PBS for 15 min, immersed in 3 % hydrogen peroxide
for 10 min, washed with distilled water and PBS for 15 min,
blocked with 10 % normal goat serum for 10 min at room
temperature, and incubated with primary antibodies at 4 
overnight. After incubation with primary antibodies, coverslips
were rinsed twice in PBS for 15 min, incubated with biotin-
labeled secondary antibody at 37  for 10 min, rinsed twice in
PBS for 15 min, and then incubated in streptavidin-peroxidase
at 37  for 10 min. The antigen-antibody complex was
visualized with diaminobenzidine (DAB) substrate. Negative
controls were incubated in the absence of primary antibodies.
Figure 1  Immunocytochemistry analysis of the effects of tachyplesin on the protein levels of mutant p53, p16, cyclin D1, CDK4 in
SMMC-7721 cells ( 536). The protein levels of mutant p53 (A), cyclin D1 (E), CDK4 (G) were high in SMMC-7721 cells while the
levels of mutant p53 (B), cyclin D1 (F), CDK4 (H) were decreased by tachyplesin. The level of p16 protein was low in SMMC-7721
cells (C) while high in the tachyplesin-treated cells (D).






SMMC-7721 cells and the cells treated with 3.0 mg/L tachyplesin
for 5 days were seeded in little penicillin bottles with coverslips
for 48 hours respectively. In situ hybridization procedure was
carried out as described by Spector[11] with minor modifications.
The coverslips were rinsed twice in PBS, prefixed with methanol/
acetone (1:1, v/v) for 10 min, incubated in 0.1 M HCl for 10
min, rinsed in 0.01 M PBS for 5 min×2, and incubated in 25
mg/L proteinase K at 37  for 20 min and in 0.2 % glycine in
PBS for 5 min×3. They were postfixed in 4 % paraformaldehyde
for 10 min, dehydrated, and air dried. The prehybridization was
conducted at room temperature for 1 hour, followed by
hybridization in a humid chamber at 42  for 16-22 hours. The
hybridization solution contained prehybridization solution and
1.0 ug/mL digoxigenin-labeled p21WAF1/CIP1 cRNA or c-myc
cRNA probe. Coverslips were rinsed in 2×SSC at 37  for 15
min×2, in 1×SSC for 5 min×2, in 0.5×SSC for 5 min×2, in
0.2×SSC for 5 min×2, washed with Buffer I (100 mM Tris-HCl
buffer, 150 mM NaCl, pH7.5) for 5 min, and incubated with
Blocking buffer (2 % horse serum and 0.3 % Triton X-100 in
Buffer I) for 1 hour, and then incubated at 37  for 1hour in
alkaline phosphatase-conjugated anti-digoxigenin antibody
diluted 1:500 in Blocking buffer, then rinsed in Buffer I for 15
min×3, and equilibrated in Buffer II (100 mM Tris-HCl buffer,
100 mM NaCl, 50 mM MgCl2, pH9.5). The alkaline phosphatase
reaction was conducted by incubation with NBT/BCIP solution
for 20-30 min. The reaction was stopped with Buffer III (10 mM
Tris-HCl buffer, 1 mM EDTA, pH8.0). The coverslips were then
dehydrated in alcohol, cleared in xylene, and mounted on gelatin.
The negative controls were processed without labeled probes.
RESULTS
Effects of tachyplesin on the cell cycle distribution of SMMC-
7721 cells
Cell cycle kinetics of SMMC-7721 cells was analyzed by flow
cytometry. As demonstrated in Table 1, 3.0 mg/L tachyplesin
could induce an accumulation of the cells at G0/G1 phase on day
2, 4, 6, respectively. Compared with control group, the amount
of cells at G0/G1 phase increased from 48.2 % to 65.6 %, while
the quantity of cells in S phase decreased from 48.0 % to 24.8 %
after being treated with tachyplesin for 6 days. This indicated that
tachyplesin could arrest the SMMC-7721 cells at G0/G1 phase.
Table 1  Effects of 3.0 mg/L tachyplesin on the cell cycle kinet-
ics of SMMC-7721 cells
 SMMC-7721     Tachyplesin  2 d     Tachyplesin  4 d     Tachyplesin 6 d
G0/G1      48.2 %  66.5 %  61.8 %  65.6 %
S      48.0 %  29.7 %  34.8 %  24.8 %
G2/M        3.8 %    3.8 %    3.4 %    9.6 %
Effects of tachyplesin on p53, p16 protein levels in SMMC-
7721 cells
It has revealed that p53 protein detected by immunohistochemistry
is mutant p53. Immunohistochemistry showed that the level
of mutant p53 protein was high in the nucleus and cytoplasm
of SMMC-7721 cells. However, very low level of mutant p53
protein in the tachyplesin-treated cells was observed (Figure
1A and B). p16 protein was distributed mainly in the nucleolus
of SMMC-7721 cells in low level while the level of
immunohistochemistrical reaction was very high in the
tachyplesin-treated cells (Figure 1 C and D).
Effects of tachyplesin on cyclin D1, CDK4 protein levels in
SMMC-7721 cells
As shown in Figure 1E and F, the level of cyclin D1 protein
was high in the nucleolus and cytoplasm of untreated cells
while it was very weak in the cells treated with tachyplesin.
It also revealed that exposure of SMMC-7721 cells to
tachyplesin resulted in an obvious decrease of CDK4 protein
level (Figure 1 G and H).
Figure 2  In situ hybridization analysis of p21WAF1/CIP1 and c-myc mRNA in untreated and tachyplesin-treated SMMC-7721 cells (
536). The level of p21WAF1/CIP1 mRNA was low in SMMC-7721 cells (A) but high in the tachyplesin-treated cells (B). High level of c-myc
mRNA was observed in SMMC-7721 cells (C) while the level of c-myc mRNA in the tachyplesin-treated cells down-regulated (D).
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Effects of tachyplesin on p21WAF1/CIP1, c-myc mRNA levels in
SMMC-7721 cells
To investigate the effects of tachyplesin on the expression of
tumor suppressor gene and oncogene associated with the G0/
G1 arrest, the levels of p21WAF1/CIP1 and c-myc mRNA were
also detected. In situ hybridization assay showed that the level
of p21WAF1/CIP1 mRNA was low in the nuclear and cytoplasm of
the untreated cells while it was high in the cytoplasm around
the nucleolus in the cells treated with tachyplesin (Figure 2A
and B). And high level of c-myc mRNA was observed in the
cytoplasm of SMMC-7721 cells. However, the level of c-myc
mRNA was down-regulated in the tachyplesin-treated cells
(Figure 2 C and D).
DISCUSSION
In multi-cellular organism, the balance among cell proliferation,
cell differentiation and cell death maintains a constant cell
number. Cell proliferation depends on the cell’s growth and
division cycles, which are governed by periodic assembly of
the core cell cycle clock, composed of cyclins and cyclin-
dependent kinases (CDKs)[7,12]. Distinct cyclins associate and
activate different CDKs throughout the cell cycle. The activity
of cyclin/CDK complexes is modulated by both activating and
inhibiting phosphorylation of the CDKs, and by binding to
cyclin-dependent kinases inhibitors (CKIs). In higher
eukaryotic cells, signals that arrest the cycle usually act at a G1
checkpoint. The G1 checkpoint can be viewed as a master
checkpoint of the mammalian cell cycle[7,13]. Regulation of the
G1 phase of the cell cycle is extremely complicated and involves
many different families of cyclins, CDKs and CKIs. In
eukaryotes, D-cyclins (D1, D2, and D3) bind CDK4 /6 to wire
external signals to the cell cycle and regulate progression
through mid-G1. cyclin E binds CDK2 in late G1 and its activity
is rate-limiting for progression from G1 to S phase[14]. The p16
tumor suppressor belongs to the INK4 family of CKIs. p16
specifically inhibit CDK4/6 by preventing binding of the
activating cyclin subunits. p21WAF1/CIP1, one CKI of CIP/KIP
family, unlike p16, binds to a number of cyclin/CDK
complexes such as cyclin D1/CDK4, cyclin E/CDK2 and cyclin
A/CDK2, inhibits kinases activities and induces cell cycle arrest
and cell differentiation[7,15-17].
     In addition, some other genes are associated with G1
checkpoint. It is known that wild-type p53 gene has anti-
proliferation, anti-transforming and inducing apoptosis
activities. Growth arrest induced by wild-type p53 blocks cells
prior to or near the checkpoint in late G1 phase. Mutations of
p53 are observed with a high incidence in most cancer[18,19].
One of the phenotype effects of mutant p53 protein is called
dominant-negative effect, which mutant p53 can override the
normal inhibitory function of wild-type p53. In the meantime,
c-myc gene, an early-response gene necessary for cell cycle
progression (G1-S transition), also plays an essential role in
the regulation of the cell cycle and differentiation[20-24].
      As revealed by many experiments, the regulation of G1/S
checkpoint was abnormal in tumor cells. G0/G1 arrest was a
common phenomenon in the cells undergoing induction of
differentiation. And many differentiation inducers could arrest
tumor cells in G0/G1 phase and alter the expression of cell cycle
regulators[25-31]. Our results showed that tachyplesin could
down-regulate the levels of mutant p53, cylin D1, CDK4
proteins and c-myc mRNA, up-regulate the levels of p16
protein and p21WAF1/CIP1 mRNA in SMMC-7721 cells, and arrest
the cell in Go/G1 phase as other inducers on tumor cells. Taken
together, the results indicated that tachyplesin might decrease
the kinase activity of cyclin D1/CDK4 complex by decreasing
the expression of mutant p53 protein and increasing the levels
of p16 and p21WAF1/CIP1, and suppress the phosphorylation of
retinoblastoma (Rb) protein and downregulate the level of c-
myc mRNA, which cause a decrease of the cell in S phase
significantly and arrest most of the cells at G0/G1 phase, and
induce the cells to terminal differentiation as other inducers.
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